India’s Cadila, Swedish NovaSAID To Collaborate On Developing Global Drugs
This article was originally published in PharmAsia News
Cadila Pharmaceuticals and NovaSAID signed a co-development agreement giving the India drug maker exclusive rights to develop and market the Swedish firm's drugs in Africa, India and the Middle East.
You may also be interested in...
The race is now on to get formal adoption of European Commission proposal postponing the MDR by one year and allowing more devices on the market more quickly. But potential hurdles are in the way as experts advise caution.
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.